Insider Selling: Artivion (NYSE:AORT) SVP Sells 6,393 Shares of Stock

by · The Markets Daily

Artivion, Inc. (NYSE:AORT – Get Free Report) SVP Jean Holloway sold 6,393 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $45.00, for a total transaction of $287,685.00. Following the transaction, the senior vice president directly owned 163,408 shares in the company, valued at $7,353,360. The trade was a 3.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Artivion Stock Performance

Shares of NYSE:AORT traded up $0.32 on Tuesday, reaching $45.44. The company’s stock had a trading volume of 149,362 shares, compared to its average volume of 433,748. The stock’s 50-day moving average is $42.72 and its two-hundred day moving average is $36.51. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.04. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The stock has a market capitalization of $2.15 billion, a P/E ratio of -108.26 and a beta of 1.65.

Artivion (NYSE:AORT – Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. The firm had revenue of $113.39 million for the quarter, compared to analyst estimates of $110.71 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company’s quarterly revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Trading of Artivion

A number of institutional investors have recently added to or reduced their stakes in AORT. Aster Capital Management DIFC Ltd raised its position in Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares during the period. MCF Advisors LLC raised its holdings in shares of Artivion by 109.3% during the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock valued at $29,000 after buying an additional 614 shares during the period. Smartleaf Asset Management LLC raised its holdings in shares of Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after buying an additional 538 shares during the period. State of Wyoming acquired a new position in Artivion during the 3rd quarter worth approximately $80,000. Finally, Quadrant Capital Group LLC purchased a new position in Artivion in the 3rd quarter worth approximately $92,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on AORT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, October 8th. Needham & Company LLC boosted their target price on shares of Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Wall Street Zen upgraded shares of Artivion from a “buy” rating to a “strong-buy” rating in a report on Saturday. Oppenheimer restated an “outperform” rating and set a $50.00 target price on shares of Artivion in a research report on Friday, November 7th. Finally, Canaccord Genuity Group increased their price target on Artivion from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $49.11.

Check Out Our Latest Research Report on AORT

About Artivion

(Get Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Featured Articles